High Tumor Mutation Burden Predicts Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinoma Treated With Targeted Therapy

被引：0
|
作者：
Lee, S. H. [1 ]
Sung, J. [2 ]
机构：
[1] Kyung Hee Univ, Dept Internal Med, Seoul, South Korea
[2] Kyung Hee Univ, Dept Pathol, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
predictive biomarker; tumor mutation burden; EGFR-TKI;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA14.06
引用
收藏
页码：S932 / S932
页数：1
相关论文
共 50 条
  • [1] High tumor mutation burden predicts unfavorable clinical outcome in EGFR-mutated lung adenocarcinoma treated with targeted therapy.
    Lee, Seung Hyeun
    Sung, Ji-Youn
    CANCER RESEARCH, 2021, 81 (13)
  • [2] High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
    Sung, Ji-Youn
    Park, Dong-Won
    Lee, Seung-Hyeun
    BIOMEDICINES, 2022, 10 (09)
  • [3] High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
    Yoon, Byung Woo
    Chang, Boksoon
    Lee, Seung Hyeun
    ONCOTARGETS AND THERAPY, 2020, 13 : 8273 - 8285
  • [4] High PD-L1 Expression is Aassociated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
    Lee, S. H.
    Chang, B.
    Yoon, B. W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S611 - S612
  • [5] The Effect of Tumor Microenvironment on Autophagy and Sensitivity to Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma
    Li, Yuan-Yuan
    Lam, Sze-Kwan
    Zheng, Chun-Yan
    Ho, James Chung-Man
    JOURNAL OF CANCER, 2015, 6 (04): : 382 - 386
  • [6] Outcome of EGFR-Mutated and Non-Mutated Lung Adenocarcinoma Receiving Standard Therapy - A Nepalese Cohort
    Dulal, S.
    Paudel, B.
    Shah, A.
    Neupane, P.
    Acharya, B.
    Chapagain, S.
    Karn, A.
    Shilpakar, R.
    Thapa, R.
    Gautam, B.
    Brustugun, O. T.
    Leighl, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S927 - S927
  • [7] Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs
    Lee, S. H.
    Park, M. J.
    Chang, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S572 - S572
  • [8] Positive PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with EGFR-TKIs
    Lee, Seung Hyeun
    Park, Myung Jae
    Chang, Boksoon
    CANCER RESEARCH, 2019, 79 (13)
  • [9] Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs
    Jeon, W.
    Lim, B.
    Han, S.
    Kwack, W.
    Chang, B.
    Choi, H.
    Kim, Y.
    Choi, C.
    Park, M.
    Yoo, J.
    Lee, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [10] Targeted NGS analysis to predict recurrence in resected EGFR-mutated lung adenocarcinoma
    Kim, In Ae
    Kim, Hee Jung
    Hur, Jae Young
    Lee, Seung En
    Park, Jung Hoon
    Lee, Song Am
    Hwang, Jae Jun
    Kim, Wan Seop
    Lee, Kye Young
    CANCER RESEARCH, 2020, 80 (16)
12345